TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT00563784
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Erlotinib — DRUG
    150 mg by mouth daily for 7 Weeks
  • Carboplatin — DRUG
    2 AUC by vein weekly for 7 Weeks
  • Paclitaxel — DRUG
    45 mg/m\^2 by vein weekly for 7 Weeks
  • Radiation Therapy — RADIATION
    63 GY/35 fractions for 7 weeks (+/- 5 days)

Study Details

The goal of this clinical research study is to find out if erlotinib given with chemotherapy and radiation therapy can help to control NSCLC. The safety of this combination treatment will also be studied. Researchers will also test the tissue from your earlier biopsy to measure the levels of epidermal growth factor receptor (EGFR). The purpose of EGFR testing is to learn about any link between various forms of EGFR and your response to treatment with erlotinib.

Key Dates

First listed
Nov 26, 2007
Start date
Nov 30, 2007
Status verified
Nov 2019
Primary completion
May 30, 2018
Completion
May 30, 2018

Study Design

Enrollment
68 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Erlotinib + Paclitaxel + Carboplatin
    Oral Erlotinib 150 mg daily + Paclitaxel 45 mg/m\^2 by vein weekly + Carboplatin 2 AUC by vein weekly and Radiation Therapy 63 GY/35 fractions for 7 weeks cycles

Primary Outcome Measure

Time To First Disease Progression [ Time Frame: From date of registration until the date of first documented progression or death from any cause, or lost to follow up, whichever came first, assessed up to 5 years. ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of Texas MD Anderson Cancer CenterHoustonTexas77030-

Find similar trials in Houston, TX

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
University of Texas MD Anderson Cancer Center· Houston, TX

Related Studies